Put the EUA for Baricitinib Plus Remdesivir in Perspective
The oral rheumatoid arthritis med baricitinib (Olumiant) is now authorized to treat COVID-19 in hospitalized patients.
It's a Janus kinase (JAK) inhibitor that blocks cytokines to decrease inflammation. Plus it may have antiviral effects.
Explain that evidence suggests ADDING baricitinib to remdesivir (Veklury) reduces recovery time by 1 day...compared to remdesivir alone. But it's too soon to say if the combo reduces mortality.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote